TABLE 5

In vitro effects of nicotine in combination with chemotherapy on lung cancer under nonphysiologic conditions and/or with nonpharmacological concentrations of nicotine

Lung Cancer Cell LineNicotineChemotherapyDuration of TreatmentSerum ConcentrationCellular Response (Assay)Result (Relative to Chemotherapy Alone)Reference
A5491 μMCisplatin 20 μM24 h0% for 36 h, then treatedApoptosis (TUNEL)40% decrease*Dasgupta et al. (2011)
H4462.5–15 μMCisplatin 10 μM12–72 h10%Viability (MTT)10%–20% increase (2.5 μM),Zeng et al. (2012)
0%–50% decrease (5–15 μM)
36 hApoptosis (AV/PI)25%–50% decrease*
A549, H1299, H231 μMCisplatin 20 μM36 h0%Apoptosis (TUNEL)20%–40% decreaseDasgupta et al. (2006)
Gemcitabine 20 μM20%–25% decrease
Paclitaxel 20 μM25%–50% decrease
N417Previous nicotine exposure (500 μM for 7 days)Cisplatin (5–100 μM)48 h10%Viability (MTT)50% increase*Martínez-García et al. (2010)
Etoposide (5–100 μM)50% increase*
Mitomycin (5–50 μM)IC50 10 μM → 20 μM*
Paclitaxel (5–100 μM)IC50 35 μM → 70 μM*
201T10 μMGefitinib 35 μM48 h10%Viability (MTS)47% increase (10 μM)*Carlisle et al. (2007)
A5491 μMGemcitabine 10 μM36 h0% for 24 h, then treatedApoptosis (TUNEL)20% decrease*Guo et al. (2013)
H157, H170310 μMPaclitaxel 100 nM48 h0.1%Apoptosis (sub-G1)8% decrease*Tsurutani et al. (2005)
Etoposide 100 μM15% decrease*
  • AV/PI, annexin V/propidium iodide; MTS, (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium); MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.

  • * Statistically significant.

  • Statistical significance not indicated.